In the PARADIGM-HF trial, sacubitril/valsartan was superior to the ACE inhibitor enalapril in patients with symptomatic HFrEF.16 Our findings are not directly comparable given the differences in both the patients studied and comparator therapy. The gene discussed is ACE; the disease is hydrops fetalis.